San Antonio Breast Cancer Symposium 2023

The San Antonio Breast Cancer Symposium (SABCS) is an annual event that brings together thousands of international clinicians and scientists in an effort to share the latest advancements in breast cancer research. It is designed to provide updates on clinical, translational, and basic research findings through a forum dedicated to interaction and education among international researchers and healthcare professionals.

SABCS 2023 marks the 46^th anniversary of the event, with over 10,000 clinicians and scientists set to attend and present their recent findings. The event comprises of formal lectures, poster presentations, forums, and case discussions. Members of the Mass General Cancer Center will present at SABCS, sharing their research in the prevention, diagnosis, and treatment of breast cancer and premalignant breast disease.

Wednesday, December 6, 2023

Circulating Tumor DNA Dynamics in Acelera Breast Cancer: A Phase II Study of Giredestrant for Estrogen Receptor-positive, HER2-Negative, Previously Treated Advanced Breast Cancer

Poster Session 1
12:00 p.m. – 2:00 p.m. in Halls 2-3
Ann Collier, Aditya Bardia, Joo Hyuk Sohn, Elgene Lim, Marianna Chavez, Miguel Martín, Jorge Martinalbo, Pablo Perez-Moreno, Heather Moore

Trial in Progress: Open-label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or ER+/HER2- Metastatic Breast Cancer With an ESR1 Mutation

Poster Session 1
12:00 p.m. – 2:00 p.m. in Halls 2-3
Matthew Goetz, Seth Wander, Thomas Bachelot, Gerald Batist, Javier Cortés, Massimo Cristofanilli, Giuseppe Curigliano, Alexandre de Nonneville, Einav Nili-Gal Yam, Komal Jhaveri, Cynthia Ma, Heather Parsons, Hope Rugo, Sarah Sammons, Daniel Stover, Chris Twelves, Aditya Bardia, Paul V. Plourde, David J Portman, Senthil Damodaran

VERITAC-2: A Phase 3 Study of Vepdegestrant, a Proteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER–Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

Poster Session 1
12:00 p.m. – 2:00 p.m. in Halls 2-3
Mario Campone, Cynthia Ma, Michelino de Laurentiis, Hiroji Iwata, Sara Hurvitz, Seth Wander, Michael Danso, Dongrui Lu, Julia Perkins Smith, Yuan Liu, Lana Tran, Sibyl Anderson, Erika Hamilton

STX-478-101: A Phase 1/2, First-in-Human Study of STX-478 Monotherapy or in Combination With Fulvestrant in Patients With Breast Cancer or Other Advanced Solid Tumors (Trial in Progress)

Poster Session 1
12:00 p.m. – 2:00 p.m. in Halls 2-3
Alberto Montero, Douglas Orr, Pamela Munster, Patricia LoRusso, Komal Jhaveri, Timothy Pluard, Ira Winer, Michael Streit, Monica Patterson, Simon Roberts, Stefani Corsi-Travali, Courtney Ewert, Dejan Juric

A Bedside-to-Bench Translational Analysis Demonstrates That NF1 Alterations Promote CDK4/6 Inhibitor (CDK4/6i) Resistance in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (MBC)

Poster Session 1
12:00 p.m. – 2:00 p.m. in Halls 2-3
Maxwell Lloyd, M Rosario Chica-Parrado, Todd Knepper, Chang-Ching Lin, Emily Podany, Christine Walko, Fabiana Napolitano, Caroline Weipert, Jiemin Liao, Arielle Medford, Lianne Ryan, Jennifer Keenan, Nicole Zhang, Shiyuan Liu, Gerburg Wulf, Katherine Clifton, Cynthia Ma, Hyo Han, Leif Ellisen, Aditya Bardia, Carlos Arteaga, Ariella Hanker, Seth Wander

Coordinated Care of Brain Metastasis

Educational Session 2
3:10 p.m. – 5:00 p.m. in Hemisfair Ballroom 3
Co-Presenter: Helen A. Shih

Effect of Alpelisib Dose Modification for AE Management on Progression-free Survival and Treatment Duration in SOLAR-1 and BYLieve Clinical Trials

Poster Session 2
5:00 p.m. – 7:00 p.m. in Halls 2-3
Hope Rugo, Alessandra Gennari, Stephen Chia, Dejan Juric, Neil Vasan, Sherko Küemmel, Patrick Neven, Florence Lerebours, Manuel Ruíz – Borrego, Pedram Razavi, Jyotika Singh, Yogesh Chattar, Murat Akdere, Eva Ciruelos

ELEVATE: A Phase 1b/2, Open-label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (Pts) With Estrogen Receptor-Positive (ER+), HER2-Negative (HER2-) Locally Advanced or Metastatic Breast Cancer (Mbc)

Poster Session 2
5:00 p.m. – 7:00 p.m. in Halls 2-3
Hope Rugo, Aditya Bardia, Javier Cortés, Giuseppe Curigliano, Erika Hamilton, Sara Hurvitz, Sibylle Loibl, Sara Tolaney, Virginia Kaklamani, Giulia Tonini, Shannon Matheny, Kathy Puvana Theall, Joyce O'Shaughnessy

Five-year Quality of Life (QOL) Trajectories Among Young Breast Cancer (BC) Survivors

Poster Session 2
5:00 p.m. – 7:00 p.m. in Halls 2-3
Tal Sella, Zheng Yue, Kathryn Ruddy, Shari Gelber, Rulla Tamimi, Jeffrey Peppercorn, Lidia Schapira, Virginia Borges, Steven Come, Eric Winer, Ann Partridge, Shoshana Rosenberg

Baseline Genomic Alterations and the Activity of Lasofoxifene (LAS) Plus Abemaciclib (Abema) in Patients With ER+/HER2- Metastatic Breast Cancer (Mbc): The ELAINE 2 Study

Poster Session 2
5:00 p.m. – 7:00 p.m. in Halls 2-3
Senthil Damodaran, Massimo Cristofanilli, Matthew Goetz, Ciara O'Sullivan, Gary Riordan, Hope Rugo, Daniel Stover, Seth Wander, Dominic Carroll, Paul V. Plourde, David J Portman, Einav Nili-Gal Yam

Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan in Patients With Localized Breast Cancer (Neostar)

Poster Session 2
5:00 p.m. – 7:00 p.m. in Halls 2-3
Laura Spring, Ana Garrido-Castro, Filipa Lynce, Nadine Tung, Rachel Abelman, Lianne Ryan, Megan Moran, Elizabeth Mittendorf, Leif Ellisen, Sara Tolaney, Aditya Bardia

INAVO121: Phase III Study of Inavolisib + Fulvestrant vs Alpelisib + Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated Locally Advanced or Metastatic Breast Cancer

Poster Session 2
5:00 p.m. – 7:00 p.m. in Halls 2-3
Dejan Juric, Kevin Kalinsky, Seock-Ah Im, Eva Ciruelos, Giampaolo Bianchini, Carlos Barrios, William Jacot, Peter Schmid, Sherene Loi, Hope Rugo, Veronica Craine, Katherine Hutchinson, Aulde Flechais, Eirini Thanopoulou, Nadia Harbeck

VERITAC-3: A Randomized Phase 3 Study, With a Lead-in, of First-line Vepdegestrant + Palbociclib vs Letrozole + Palbociclib in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Poster Session 2
5:00 p.m. – 7:00 p.m. in Halls 2-3
Seth Wander, Erika Hamilton, Mario Campone, Michael Danso, Sara Hurvitz, Hiroji Iwata, Colombe Chappey, Derek Yang, Julia Perkins Smith, Yuan Liu, Yuanyuan Zhang, Sibyl Anderson, Michelino de Laurentiis

Sequencing Antibody-drug Conjugate After Antibody-drug Conjugate in Metastatic Breast Cancer (A3 Study): Multi-institution Experience and Biomarker Analysis

Poster Spotlight Session 3
5:30 p.m. – 6:30 p.m. in Hemisfair Ballroom 1-2
Rachel Occhiogrosso Abelman

Thursday, December 7, 2023

Randomised Phase 3 Study of Datopotamab Deruxtecan vs Chemotherapy for Patients With Inoperable or Metastatic Hormone Receptor-Positive, HER2- Breast Cancer: Efficacy, Safety and Biomarker Results From TROPION-Breast01

General Session 2
8:15 a.m. – 11:15 a.m. in Hall 1
Aditya Bardia

Unmet Clinical Need in Patients With Pre-treated Hormone Receptor-Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer in Routine Care: A Targeted Literature Review

Poster Session 3
12:00 p.m. – 2:00 p.m. in Halls 2-3
Laura Spring, Simon M Collin, Inderjit K Dhillon, Gráinne Long, Evelina Bertranou, Komal Jhaveri, Aditya Bardia

SUMIT-ELA: Phase 1b/2 Combination of Cyclin-dependent Kinase 7 Inhibitor (CDK7i) Samuraciclib and Selective Estrogen Receptor Degrader (SERD) Elacestrant in Advanced Hormone Receptor Positive (HR+) Breast Cancer After CDK4/6i

Poster Session 3
12:00 p.m. – 2:00 p.m. in Halls 2-3
Amita Patnaik, Silvia Antolin Novoa, Meritxell Bellet- Ezquerra, Francois-Clement Bidard, Valentina Boni, Maxime Brunet, Mario Campone, Carlos Garay, Raquel Gómez-Bravo, Sacha Howell, Rinath Jeselsohn, Simon Lord, Paolo Mazzei, Maria De Miguel, Erin Roesch, Agostina Stradella, Helene Vanacker, Cecile Vicier, Seth Wander, Glen Clack, Stuart McIntosh

A Multi-institutional Review of Contralateral Axillary Metastases: Time for Reclassification as Local-regional Event?

Poster Session 3
12:00 p.m. – 2:00 p.m. in Halls 2-3
Meghan R. Flanagan, Stephanie Downs-Canner, Samantha Thomas, Astrid Botty van de bruele, Margaret Lillie, Kristalyn Gallagher, Tammeza Gibson, James Jakub, Alexandra Verosky, Sarah Tevis, Malia Brennan, Francys Verdial, Jennifer Q. Zhang, Leisha Elmore, Jennifer Plichta, Laura Rosenberger

Practice Patterns for Sequential Use of Antibody-drug Conjugate After Antibody-drug Conjugate in Metastatic Breast Cancer: Results From a Physician Survey

Poster Session 3
12:00 p.m. – 2:00 p.m. in Halls 2-3
Yara Abdou, Prarthna Bhardwaj, Rachel Abelman, Laura Spring, Aditya Bardia, Lisa Carey, Priyanka Sharma

Personalized ctDNA Testing for Detection of Molecular Residual Disease in Patients With Localized HR+ Breast Cancer: Temporal Dynamics and Impact on Clinical Outcomes

Poster Session 3
12:00 p.m. – 2:00 p.m. in Halls 2-3
Arielle Medford, Elyssa Denault, Zanta Ephrem, Douglas Micalizzi, Yael Bar, Rachel Abelman, Amy Comander, Justine Knape, Minetta Liu, Angel Rodriguez, Steven Isakoff, Beverly Moy, Laura Spring, Aditya Bardia

First-in-Human Phase 1A Study of RGT-419B, a Next Generation CDK4 Inhibitor, in Patients (Pts) With Hormone Receptor Positive (HR+) HER2- Advanced/Metastatic Breast Cancer (ABC) Who Progressed on Prior CDK4/6 Inhibitors (CDK4/6i)

Poster Session 3
12:00 p.m. – 2:00 p.m. in Halls 2-3
Seth Wander, Dave Valacer, Richard Zuniga, Heather Yeckes-Rodin, Christopher Perkins, Lisa Ge, Lili Yao, Jing Lin, Dawn Begley, Feifei Sun, Andie Zheng, Jing Han, Zhi (Julie) Xie, Aditya Bardia, Kevin Kalinsky

First-in-Human Global Study of RLY-2608, a Pan-mutant and Isoform Selective PI3Kα Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Poster Session 3
12:00 p.m. – 2:00 p.m. in Halls 2-3
Andreas Varkaris, Komal Jhaveri, Elena Garralda Cabanas, Lucia Sanz, Janice Kim, Cesar A. Perez, Erika Hamilton, Alexander I. Spira, Kari Wisinski, Angel Guerrero, Jason Henry, Jordi Rodon Ahnert, Gege Tan, Xiaoyan Li, Diana Hummel, Tamieka Hunter, Alison Timm, Ramin Samadani, Erika PuentePoushnejad, Eunice Kwak, Brenton G. Mar, Alison M. Schram

A First-in-Human Study of the Highly Selective PI3Kα Inhibitor RLY-5836 in Patients With Advanced Breast Cancer and Other Solid Tumors

Poster Session 3
12:00 p.m. – 2:00 p.m. in Halls 2-3
Andreas Varkaris, Steven Isakoff, Cesar A. Perez, Bert O'Neil, Erika Hamilton, Erin Conlin, Gege Tan, Xiaoyan Li, Alison Timm, Ramin Samadani, Erika Puente-Poushnejad, Eunice Kwak, Brenton G. Mar, Alison M. Schram

MRI Radiomic Phenotypes Derived From the ECOG-ACRIN E4112 Trial to Assess High-risk Ductal Carcinoma In Situ

Poster Session 3
12:00 p.m. – 2:00 p.m. in Halls 2-3
Kalina Slavkova, Ruya Kang, Vivian Belenky, Anum Kazerouni, Debosmita Biswas, Hannah Horng, Rhea Chitalia, Michael Hirano, Jennifer Xiao, Ralph Corsetti, Sarah Javid, Derrick Spell, Antonio Wolff, Joseph Sparano, Seema Khan, Christopher Comstock, Justin Romanoff, Jon Steingrimsson, Constantine Gatsonis, Constance Lehman, Savannah Partridge, Despina Kontos, Habib Rahbar

Exposure–response Analyses of GO39932: A Phase Ia/B Study of Giredestrant in Estrogen Receptor-positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Poster Session 4
5:00 p.m. – 7:00 p.m. in Halls 2-3
Komal Jhaveri, Yi Ting (Kayla) Lien, Nicholas Turner, Elgene Lim, Maureen Cannon, Richard Anziano, Jurgen Langenhorst, Kenta Yoshida, Vikram Malhi, Mary Gates, Jennifer Eng-Wong, Chunze Li, Mona Shah, Pablo Perez-Moreno, Jiajie Yu, Aditya Bardia

Early Discontinuation of Adjuvant Chemotherapy in Older Adults With Early Breast Cancer: Results From the Prospective Multicenter HOPE Study

Poster Session 4
5:00 p.m. – 7:00 p.m. in Halls 2-3
Jingran Ji, Canlan Sun, Rachel Freedman, Harvey Cohen, Heidi Klepin, William Tew, Beverly Moy, Andrew Chapman, Tanya Wildes, Efrat Dotan, Allison Magnuson, Tracey O'Connor, Mary Anne Fenton, Heeyoung Kim, Vani Katheria, Cary Gross, Hyman Muss, Mina Sedrak

Patient Reported Outcomes From a Multi-site, Prospective Pivotal Study Evaluating Pegulicianine Fluorescence Guided Surgery (Pfgs) for Breast Cancer Lumpectomy Procedures Using the Lumicell Direct Visualization System (DVS)

Poster Session 4
5:00 p.m. – 7:00 p.m. in Halls 2-3
Kelly Hunt, Irene Wapnir, E Shelley Hwang, David Carr, Peter Blumencranz, Kate Smith, Manna Chang, Jorge Ferrer, Barbara Smith

Differential Genomic Profiling of Progesterone Receptor (PR) Negative, Estrogen Receptor (ER) Positive HER2-Negative Metastatic Breast Cancer (MBC) Through Circulating Tumor DNA

Poster Session 4
5:00 p.m. – 7:00 p.m. in Halls 2-3
Lorenzo Gerratana, Andrew Davis, Arielle Medford, Carolina REDUZZI, Katherine Clifton, Emily Podany, Whitney Hensing, Marko Velimirovic, Ami N. Shah, Lorenzo Foffano, Laura Munoz Arcos, Eleonora Nicolò, Charles S. Dai, Jennifer Keenan, Amir Behdad, Seth Wander, William Gradishar, Cynthia Ma, Fabio Puglisi, Aditya Bardia, Massimo Cristofanilli

Genomic Landscape Characterization After Exposure to Cyclin Dependent Kinase 4/6 Inhibitors: A Retrospective Multi-institutional Consortium Analysis

Poster Session 4
5:00 p.m. – 7:00 p.m. in Halls 2-3
Letizia Pontolillo, Carolina REDUZZI, Andrew Davis, Lorenzo Gerratana, Arielle Medford, Katherine Clifton, Whitney L. Hensing, Marko Velimirovic, Ami N. Shah, Jeannine Donahue, Laura Munoz Arcos, Charles S. Dai, Jennifer Keenan, Amir Behdad, William Gradishar, Emilio Bria, Cynthia Ma, Aditya Bardia, Massimo Cristofanilli

Real-world (RW) Utilization and Patient Outcomes Across Three CDK4/6 Inhibitors in Metastatic Breast Cancer (Mbc)

Poster Session 4
5:00 p.m. – 7:00 p.m. in Halls 2-3
Caroline Weipert, Seth Wander, Andrew Davis, Leslie Bucheit, Jayati Saha, Jiemin Liao, Nicole Zhang, Daniel Stover, Aditya Bardia, Massimo Cristofanilli

Phase II Study of a PARP Inhibitor, Talazoparib, in HER2- Metastatic Breast Cancer With a Somatic BRCA1/2 Mutation Present in Cell-free DNA or Tumor Tissue Genotyping

Poster Session 4
5:00 p.m. – 7:00 p.m. in Halls 2-3
Neelima Vidula, Senthil Damodaran, Manali Bhave, Hope Rugo, Ami N. Shah, Erica Blouch, Nathan Royce Ruffle-Deignan, Ogadinma Ogbenna, Lisa E. Flaum, Massimo Cristofanilli, Joseph Sparano, Harry Ostrer, Vandana Abramson, Nora Horick, Aditya Bardia

A Phase II Multi-institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients

Poster Session 4
5:00 p.m. – 7:00 p.m. in Halls 2-3
Mylin Torres, Jolinta lin, Sarah Friend, Canhua Xiao, Yichun Cao, Shannon Kahn, Karen Godette, Sheela Hanasoge, David Yu, Tony Eng, Matthew Cheney, Nancy Wiggers, Andrew Pippas, Keerthi Gogineni, Jane Meisel, David Schuster, Aditya Bardia, Andrew Miller, Jennifer Felger, Jeffrey Switchenko, Amelia Zelnak, Kevin Kalinsky, Manali Bhave

Immune Related Adverse Events in Patients ≥65 Years Vs. <65 Years With Breast Cancer Treated With Immunotherapy

Poster Spotlight Session 5
5:30 p.m. – 6:30 p.m. in Hemisfair Ballroom 1-2
Neelima Vidula

Friday, December 8, 2023

Breast Cancer Index and Comparative Analysis of Late Distant Recurrence Risk With Results From the TEAM Trial

Poster Session 5
12:00 p.m. – 2:00 p.m. in Halls 2-3
John MS Bartlett, Yi Zhang, Gregory Pond, Jenna Wong, Keying Xu, Melanie Spears, Elizabeth Mallon, Karen Taylor, Annette Hasenburg, Christos Markopoulos, Luc Dirix, Caroline Seynaeve, Cornelis J.H. van de Velde, Daniel Rea, Adam Brufsky, Olle Stål, Dennis Sgroi, Catherine Schnabel, Kai Treuner, Jane Bayani

Genomic Differences of Primary Triple Negative Breast Cancer in Patients Younger Than 45 Years vs. Patients Older Than 45 Years of Age

Poster Session 5
12:00 p.m. – 2:00 p.m. in Halls 2-3
Neelima Vidula, Leif Ellisen, Aditya Bardia, Christina Yau

Survival in Young Women With De Novo or Recurrent Metastatic Breast Cancer

Poster Session 5
12:00 p.m. – 2:00 p.m. in Halls 2-3
Leticia Varella, Yue Zheng, Shoshana Rosenberg, Gregory Kirkner, Craig Snow, Kathryn Ruddy, Rulla Tamimi, Jeffrey Peppercorn, Lidia Schapira, Virginia Borges, Steven Come, Laura Collins, Ellen Warner, Kate Dibble, Eric Winer, Ann Partridge

Detection of SPEN Mutations in Advanced Breast Cancer by Circulating Tumor Cell-free DNA

Poster Session 5
12:00 p.m. – 2:00 p.m. in Halls 2-3
Charles Dai, Haley Barnes, Arielle Medford, Annika Putur, Jennifer Keenan, Beverly Moy, Seth Wander, Ryan Corcoran, Aditya Bardia

Integration of Synonymous Mutations and Variants of Unknown Significance for Basal and Longitudinal Characterization of Metastatic Breast Cancer by Circulating Tumor DNA

Poster Session 5
12:00 p.m. – 2:00 p.m. in Halls 2-3
Elisabetta Molteni, Carolina REDUZZI, Andrew Davis, Lorenzo Foffano, Arielle Medford, Katherine Clifton, Whitney L. Hensing, Marko Velimirovic, Ami N. Shah, Laura Munoz Arcos, Charles S. Dai, Jennifer C. Keenan, Elyssa Denault, William Gradishar, Giuseppe Damante, Amir Behdad, Lorenzo Gerratana, Fabio Puglisi, Cynthia Ma, Aditya Bardia, Massimo Cristofanilli

Neoadjuvant HER2-targeted Therapy +/- Immunotherapy With Pembrolizumab (neoHIP): An Open Label Randomized Phase II Trial

Poster Session 5
12:00 p.m. – 2:00 p.m. in Halls 2-3
Heather McArthur, Jorge Henrique Santos Leal, Isaac Chan, Nisha Unni, Stephen Shiao, Joshua Gruber, Samira Syed, Namrata Peswani, Navid Sadeghi, Glenda Delgado, Dawn Klemow, Reva Basho, Meredith Carter, Mai Badran, Nasir Qureshi, Jessica Curtin, Joshua Weese, Stephanie Rice, Michelle Phillips, David Chan, Hugo Hool, Dorothy Park, Mary El-Masry, Philomena McAndrew, Swati Sikaria, Laura Spring, Aditya Bardia, Mourad Tighiouart, Farnaz Dadmanesh, Armando Giuliano, Katherine Sanchez, David Page

Clinical Outcomes by Age Subgroups in the Phase 3 Tropics-02 Study of Sacituzumab Govitecan vs Treatment of Physician’s Choice in HR+/HER2? Metastatic Breast Cancer

Poster Session 5
12:00 p.m. – 2:00 p.m. in Halls 2-3
Aditya Bardia, Peter Schmid, Sara Tolaney, Frederik Marmé, Javier Cortés, Theresa Valdez, Hao Wang, Wendy Verret, Hope Rugo

Positive Pegulicianine Fluorescence Rate in the Lumpectomy Cavity Correlates With Tumor Distance to Margins in Excised Tissue

Poster Session 5
12:00 p.m. – 2:00 p.m. in Halls 2-3
Irene Wapnir, E Shelley Hwang, Kelly Hunt, David Carr, Peter Blumencranz, Manna Chang, Kate Smith, Jorge Ferrer, Barbara Smith

Targeting Mutant ER

State-of-the-Art Session 3
1:30 p.m. – 2:30 p.m. in Hemisfair Ballroom 1-2
Moderator: Aditya Bardia